Article featured in PharmaBiz, January 14, 2023
Sami-Sabinsa Group’s successful transfer of technology from the trial to the commercial field has boosted demand for C. forskohlii in healthcare applications. The recent article in PharmaBiz highlights Sami-Sabinsa Group’s role in conceiving and carrying out this three-decade programme that has contributed to the country's export revenues, the "Make in India" initiative, and providing the farmers with an alternate livelihood.
